Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Thursday 16 April, 2020

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 9257J
GlaxoSmithKline PLC
16 April 2020
 

GlaxoSmithKline plc   (the ' Company ')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

970

 

 

£ 15.4420

965

 

 

£ 15.4420

777

 

 

 

 

 

d)

Aggregated information

 

2,712

 

Aggregated volume Price

 

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 38.8800

559

 

 

$38.8800

439

 

 

 

 

 

d)

Aggregated information

 

998

 

Aggregated volume Price

 

$38.8800

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor  

 

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

205

 

 

£ 15.4420

253

 

 

£ 15.4420

245

 

 

 

 

 

d)

Aggregated information

 

703

 

Aggregated volume Price

 

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

SVP Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

101

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

Senior Vice President and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.4420

144

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

Senior Vice President and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 38.8800

48

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

107

 

 

£ 15.4420

106

 

 

£ 15.4420

76

 

 

 

 

 

d)

Aggregated information

 

289

 

Aggregated volume Price

 

£ 15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

61

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

£ 15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Mackay

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£ 15.4420

524

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

£ 15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 38.8800

100

 

 

$ 38.8800

94

 

 

$ 38.8800

80

 

 

 

 

 

 

 

 

 

d)

Aggregated information

 

274

 

Aggregated volume Price

 

$ 38.8800

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.4420

195

 

 

£15.4420

269

 

 

£15.4420

235

 

 

 

 

 

d)

Aggregated information

 

699

 

Aggregated volume Price

 

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.4420

199

 

 

£15.4420

239

 

 

£15.4420

172

 

 

 

 

 

d)

Aggregated information

 

610

 

Aggregated volume Price

 

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.4420

86

 

 

£15.4420

122

 

 

 

 

 

d)

Aggregated information

 

208

 

Aggregated volume Price

 

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 April 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$ 38.8800

33

 

 

$ 38.8800

119

 

 

$38.8800

82

 

 

 

 

 

d)

Aggregated information

 

234

 

Aggregated volume Price

 

$ 38.8800

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£15.4420

134

 

 

£15.4420

140

 

 

£15.4420

99

 

 

 

 

 

d)

Aggregated information

 

 

373

Aggregated volume Price

£15.4420

e)

Date of the transaction

2020-04-14

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHXQLFFBZLFBBK

a d v e r t i s e m e n t